Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-Q Quarterly report for the period ending Saturday, March 31, 2018

Earnings Press Release
10-Q Quarterly Report
10-Q QoQ Changes
Aclaris Therapeutics, Inc.
Ticker: ACRS CIK: 1557746

Exhibit 99.1

Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

Management to Host Conference Call at 5:00 PM ET today

Wayne, PA – May 8, 2018 (GLOBE NEWSWIRE) –

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology, today announced financial results for the first quarter 2018 and provided an update on its clinical development and commercial programs.

“The first quarter of 2018 was a busy one as we prepared for the launch of ESKATA™ (hydrogen peroxide) Topical Solution, 40% (w/w), the first and only FDA-approved topical treatment for raised seborrheic keratosis (SK). We held the ESKATA Launch Meeting last week, and ESKATA is now officially available for physicians and their patients,” said Brett Fair, Chief Commercial Officer of Aclaris.

Commercial Update:

Successful rollout and implementation of the ESKATA Early Experience Initiative (EEI).

Program expanded to over 700 accounts to accommodate market demand for ESKATA.

Ongoing in-service programs to support successful training and product integration.

Positive initial ESKATA feedback from EEI program captured in physician and patient post-application surveys.

Aclaris sales force successful in generating a significant number of ESKATA pre-orders from targeted accounts ahead of official launch meeting.

Commenced health care provider (HCP) order processing and shipping the week of April 23, 2018.

ESKATA Launch Campaign Highlights:

ESKATA Launch Meeting held April 30 – May 4, 2018; Unveiled New ESKATA Campaign; sales force trained on new tools and resources to support a successful ESKATA launch.

ESKATA Consumer website (www.eskata.com) launched May 1, 2018; includes “Find A Doctor” resource for patients seeking ESKATA treatment.

The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Tuesday, May 8, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aclaris Therapeutics, Inc..

Continue

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1557746/000155837018004349/acrs-20180331x10q.htm